Nasal insulin spray shows promise in treatment of Alzheimer's
A small pilot study led by a US Department of Veterans Affairs (VA) researcher found that a nasal insulin spray improved memory, thinking skills and functional ability in people with mild cognitive impairment and Alzheimer’s disease. Currently, there are no effective treatments to delay or prevent Alzheimer’s, it was noted.
“This research builds on several years of preliminary work by an innovative group of VA investigators and their colleagues, and we are gratified to see the progress that is being made on behalf of Veterans and all Americans who are at risk for Alzheimer’s disease,” said VA under secretary for health Robert Petzel.
A VA team with the Geriatric Research, Education and Clinical Center at the VA Puget Sound Health Care System led the trial, which was sponsored in large part by the National Institute on Aging, part of the National Institutes of Health (NIH). The new findings appear in the September 12 Archives of Neurology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze